• 1
    Gray GE, Pinson LA. Evidence-based medicine and psychiatric practice. Psychiatr Q 2003;74:387399.
  • 2
    Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ 1996;312:7172.
  • 3
    Citrome L. Impact factor? Shmimpact factor! Psychiatry MMC 2007;4(May):5457.
  • 4
    Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2005;59:990996.
  • 5
    Citrome L. Show me the evidence: using number needed to treat. South Med J 2007;100:881884.
  • 6
    Laupacis A, Sackett DL, Roberts RS. An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 1988;318:17281733.
  • 7
    A’Court C. 10-minute consultation. Newly diagnosed hypertension. BMJ 2002;324:1375.
  • 8
    Citrome L. Can you interpret confidence intervals? It’s not that difficult Curr Psychiatry 2007;6(Aug):7782.
  • 9
    Cookson J, Gilaberte I, Desaiah D, Kajdasz DK. Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. Int Clin Psychopharmacol 2006;21:267273.
  • 10
    Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995;52:173188.
  • 11
    Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:12091223.
  • 12
    McEvoy JP, Lieberman JA, Stroup TS et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006;163:600610.
  • 13
    Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 2006;163:611622.
  • 14
    Stroup TS, Lieberman JA, McEvoy JP et al. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. Am J Psychiatry 2007;164:415427.
  • 15
    Citrome L, Stroup TS. Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians? Int J Clin Pract 2006;60:933940.
  • 16
    Citrome L. Interpreting and applying the CATIE results: with CATIE, context is key, when sorting out phases 1, 1A, 1B, 2E, and 2T. Psychiatry MMC 2007;4:2329.
  • 17
    Citrome L. The effectiveness criterion: balancing efficacy against the risk of weight gain. J Clin Psychiatry 2007;68(suppl. 12):1217.
  • 18
    Karagianis J, Rosenbluth M, Tohen M et al. Reviewing CATIE for clinicians: balancing benefit and risk using evidence-based medicine tools. Curr Med Res Opin 2007;23:25512557.
  • 19
    Citrome L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J Clin Psychiatry 2007;68:18761885.
  • 20
    Cookson J, Keck PE, Ketter TA, Macfadden W. Number needed to treat and time to response/remission for quetiapine monotherapy efficacy in acute bipolar depression: evidence from a large, randomized, placebo-controlled study. Int Clin Psychopharmacol 2007;22:93100.